New York, Feb 3, 2026, 21:00 EST — The market has closed.
- Shares climbed roughly 1% on Tuesday, settling just under $233 after hours.
- RBC Capital Markets raised its price target, highlighting ongoing concerns about talc litigation risk.
- Traders enter the next session focused on new clinical updates and upcoming management comments.
Johnson & Johnson shares climbed roughly 1% on Tuesday following an upgrade from RBC Capital Markets, which lifted its price target and kept focus on the company’s ongoing legal issues. The stock last traded at $233.10, fluctuating between $230.00 and $235.24, with about 9.3 million shares changing hands.
This matters because talc litigation remains central to the valuation debate. A “Daubert” ruling—a U.S. court’s test on whether expert evidence is reliable enough for juries—can influence trial timetables and settlement leverage, even if trading seems steady. Reuters
On the business front, the company has been ramping up new clinical messaging in oncology. On Monday, it spotlighted real-world data — drawn from routine care settings rather than controlled trials — showing a 51% lower risk of death for certain metastatic prostate cancer patients treated with ERLEADA compared to darolutamide without docetaxel (hazard ratio 0.49). “These real-world data show the survival benefit of apalutamide versus darolutamide,” said Mehmet Bilen of Emory University, according to the company statement. JNJ.com
Johnson & Johnson continues to push investors to concentrate on fresh developments — new drugs, devices, and expanding market share — even as legal battles rage over what lies ahead in court.
That divide fuels daily trading. The stock may push up on product news and analyst backing, only to hit a wall when legal developments resurface.
The downside is straightforward. Any court move that speeds trials, expands expert testimony, or drives up expected cash costs could quickly sour sentiment, even if the business keeps running smoothly. Last week, a U.S. judge tossed a lawsuit accusing the company of fraud related to its talc-bankruptcy plan, but the core cancer claims still pose a risk and appeals can drag on.
U.S. markets being closed today, all eyes now turn to whether Tuesday’s gains carry through Wednesday or slip away without new triggers. Traders remain on watch for any fresh litigation filings or analyst updates that could shift the risk outlook.
Management has a key event lined up. The company announced it will participate in the TD Cowen health care conference on March 3, featuring a fireside chat at 11:10 a.m. Eastern, which will also be webcast.
Investors are gearing up for the company’s MedTech updates at the atrial-fibrillation meeting in Boston, where new data from its electrophysiology portfolio will be unveiled. “Evidence-based innovation is the foundation of how we advance arrhythmia care,” said MedTech executive Michael Bodner ahead of the late-breaking OMNY-AF Pilot presentation set for Feb. 6 at 5:30 p.m. ET. JNJ.com
